Endometrial Cancer Clinical Trials

187 recruiting

Endometrial Cancer Trials at a Glance

205 actively recruiting trials for endometrial cancer are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 2 with 58 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running endometrial cancer studies include AstraZeneca, Memorial Sloan Kettering Cancer Center, and Dana-Farber Cancer Institute.

Browse endometrial cancer trials by phase

Treatments under study

About Endometrial Cancer Clinical Trials

Looking for clinical trials for Endometrial Cancer? There are currently 187 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Endometrial Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Endometrial Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 205 trials

Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting
Phase 1

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting
Phase 1

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

Advanced Relapsed or Refractory Germ Cell TumoursAdvanced Relapsed or Refractory Endometrial CancerAdvanced Relapsed or Refractory Ovarian Cancer
Boehringer Ingelheim187 enrolled13 locationsNCT07306559
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled3 locationsNCT07419841
Recruiting
Early Phase 1

Tirzepatide in Obesity-Driven Endometrial Cancer

Endometrial CancerObesity
UNC Lineberger Comprehensive Cancer Center20 enrolled1 locationNCT07065552
Recruiting
Phase 3

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Endometrial Cancer
BioNTech SE480 enrolled132 locationsNCT06340568
Recruiting
Phase 3

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Endometrial Cancer
Karyopharm Therapeutics Inc276 enrolled217 locationsNCT05611931
Recruiting
Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Endometrial Cancer
Merck Sharp & Dohme LLC1,123 enrolled245 locationsNCT06952504
Recruiting

REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification

Endometrial Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS264 enrolled1 locationNCT07555665
Recruiting
Phase 3

Vaginal Cuff Brachytherapy Fractionation Study

Endometrial Cancer
Kara Romano, MD258 enrolled3 locationsNCT03785288
Recruiting
Phase 1

A Study of PHST001 in Advanced Solid Tumors

Ovarian CancerEndometrial CancerCholangiocarcinoma+2 more
Pheast Therapeutics272 enrolled20 locationsNCT06840886
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Ovarian CancerOvarian CarcinomaAdvanced Solid Tumor+8 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Ovarian CancerCervical CancerEndometrial Cancer+3 more
Mayo Clinic3,110 enrolled24 locationsNCT05051722
Recruiting
Phase 1

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Breast CancerOvarian CancerEndometrial Cancer+1 more
Regor Pharmaceuticals Inc.63 enrolled3 locationsNCT07524322
Recruiting

Endometrial Cancer Vaginal Fluid Specimen Collection Study

Endometrial CancerEndometrial Intraepithelial NeoplasiaAtypical Endometrial Hyperplasia+2 more
Exact Sciences Corporation4,200 enrolled1 locationNCT07544680
Recruiting
Phase 1

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Endometrial CancerAdvanced Solid TumorMetastatic Solid Tumor+1 more
MOMA Therapeutics132 enrolled14 locationsNCT06974110
Recruiting
Phase 2

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Endometrial CancerLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+10 more
Rahul Aggarwal89 enrolled3 locationsNCT03682289
Recruiting
Phase 2

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Endometrial Cancer
Canadian Cancer Trials Group393 enrolled105 locationsNCT05640999
Recruiting

Detection of Endometrial Cancer Through Risk Modelling

Endometrial Cancer
University of British Columbia1,000 enrolled1 locationNCT06268626
Recruiting
Phase 1Phase 2

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Endometrial CancerCarcinomaGynecologic Cancer+1 more
University of Alabama at Birmingham37 enrolled1 locationNCT05559879